Eliquis, Ibrance, Xeljanz and biosimilars help drive profit growth
News
EC approves Pfizer’s Herceptin biosimilar
Copycat of blockbuster breast cancer drug is Pfizer’s first oncology biosimilar
Sanofi profits and sales fall in Q2
US patent losses continue to sting for the company
Novartis’ migraine drug gets EMA approval
Aimovig becomes Europe’s first treatment specifically designed to prevent migraine
RedHill sees positive results for anti-MAP Crohn’s drug
Drug could be “paradigm shift” in $10 billion industry
Takeda signs antibody therapy deal with HiFiBiO
Companies will research multiple targets in gastrointestinal diseases, cancers and other disorders
Keytruda-chemotherapy combination gets CHMP nod
Drug also recommended for approval in head and neck squamous cell carcinoma
Deliver on your potential
Highlighting the real difference that individual sales people can deliver to both patients and HCP’s, the PharmaTimes Sales Awards offers a crucial opportunity for learning and development against an ever changing landscape.
Are you the hottest agency in town?
You should be! Enter now and be the most talked about agency of 2019
Q2 results roundup – 27 July
The latest financial results from Amgen, Astellas, AZ, BMS and Celgene
Clinigen buys global rights to Horizon’s Imukin
The UK’s Clinigen Group has bought global rights to rare disease therapy Imukin from Horizon Pharma, for an undisclosed amount.
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
NICE backing for Keytruda in classical Hodgkin lymphoma
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
Time is running out – ENTER NOW
The prestigious PharmaTimes Marketer of the Year competition closes for entries in a matter of weeks. It only takes a few seconds to fill out the online entry form and you don’t need to do anything else until the day of the competition, so if you are thinking of entering, do it now!
GSK ups guidance and unveils major restructure
GlaxoSmithKline has upped its expectations for the year after a strong performance by its vaccines division in the second quarter and the delay of a potential generic version of Advair in the US.
